Inebilizumab, a B Cell-Depleting Anti-CD19 Antibody for the Treatment of Autoimmune Neurological Diseases: Insights from Preclinical Studies

Exaggerated or inappropriate responses by B cells are an important feature in many types of autoimmune neurological diseases. The recent success of B-cell depletion in the treatment of multiple sclerosis (MS) has stimulated the development of novel B-cell-targeting therapies with the potential for i...

Full description

Saved in:
Bibliographic Details
Published in:Journal of clinical medicine 2016-11, Vol.5 (12), p.107
Main Authors: Chen, Ding, Gallagher, Sandra, Monson, Nancy L, Herbst, Ronald, Wang, Yue
Format: Article
Language:English
Subjects:
Review
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c514t-3e0eacc6e30defddee630b813ec10066c47d90c9eb5be257f5797b148288f3003
cites cdi_FETCH-LOGICAL-c514t-3e0eacc6e30defddee630b813ec10066c47d90c9eb5be257f5797b148288f3003
container_end_page
container_issue 12
container_start_page 107
container_title Journal of clinical medicine
container_volume 5
creator Chen, Ding
Gallagher, Sandra
Monson, Nancy L
Herbst, Ronald
Wang, Yue
description Exaggerated or inappropriate responses by B cells are an important feature in many types of autoimmune neurological diseases. The recent success of B-cell depletion in the treatment of multiple sclerosis (MS) has stimulated the development of novel B-cell-targeting therapies with the potential for improved efficacy. CD19 has emerged as a promising target for the depletion of B cells as well as CD19-positive plasmablasts and plasma cells. Inebilizumab (MEDI-551), an anti-CD19 antibody with enhanced antibody-dependent cell-mediated cytotoxicity against B cells, is currently being evaluated in MS and neuromyelitis optica. This review discusses the role of B cells in autoimmune neurological disorders, summarizes the development of inebilizumab, and analyzes the recent results for inebilizumab treatment in an autoimmune encephalitis mouse model. The novel insights obtained from these preclinical studies can potentially guide future investigation of inebilizumab in patients.
doi_str_mv 10.3390/jcm5120107
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5184780</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1844025608</sourcerecordid><originalsourceid>FETCH-LOGICAL-c514t-3e0eacc6e30defddee630b813ec10066c47d90c9eb5be257f5797b148288f3003</originalsourceid><addsrcrecordid>eNpVkdtu1DAQhi0EolXpDQ-AfIkQgXGcxA4XSMsuh5UqQKJcW44z2XXlw2I7SOUZeGjSA6XMzYw0n_45_IQ8ZfCK8x5eXxjfshoYiAfkuAYhKuCSP7xXH5HTnC9gCSmbmonH5KgWUnas7o7J723AwTr7a_Z6eEk1fUfX6Fy1wYPDYsOOrkKx1XrD-utqiOMlnWKiZY_0PKEuHkOhcaKruUTr_RyQfsY5RRd31mhHNzajzpjf0G3IdrcvmU4pevo1oXE2XDPfyjxazE_Io0m7jKe3-YR8__D-fP2pOvvycbtenVWmZU2pOAJqYzrkMOI0jogdh0EyjoYBdJ1pxNiD6XFoB6xbMbWiFwNrZC3lxAH4CXl7o3uYB4-jWS5I2qlDsl6nSxW1Vf93gt2rXfypWiYbIa8Ent8KpPhjxlyUt9ksf9MB45zVgjVQtx3IBX1xg5oUc0443Y1hoK4cVP8cXOBn9xe7Q__6xf8A-8CY1g</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1844025608</pqid></control><display><type>article</type><title>Inebilizumab, a B Cell-Depleting Anti-CD19 Antibody for the Treatment of Autoimmune Neurological Diseases: Insights from Preclinical Studies</title><source>Publicly Available Content Database</source><source>IngentaConnect Journals</source><source>PubMed Central</source><creator>Chen, Ding ; Gallagher, Sandra ; Monson, Nancy L ; Herbst, Ronald ; Wang, Yue</creator><creatorcontrib>Chen, Ding ; Gallagher, Sandra ; Monson, Nancy L ; Herbst, Ronald ; Wang, Yue</creatorcontrib><description>Exaggerated or inappropriate responses by B cells are an important feature in many types of autoimmune neurological diseases. The recent success of B-cell depletion in the treatment of multiple sclerosis (MS) has stimulated the development of novel B-cell-targeting therapies with the potential for improved efficacy. CD19 has emerged as a promising target for the depletion of B cells as well as CD19-positive plasmablasts and plasma cells. Inebilizumab (MEDI-551), an anti-CD19 antibody with enhanced antibody-dependent cell-mediated cytotoxicity against B cells, is currently being evaluated in MS and neuromyelitis optica. This review discusses the role of B cells in autoimmune neurological disorders, summarizes the development of inebilizumab, and analyzes the recent results for inebilizumab treatment in an autoimmune encephalitis mouse model. The novel insights obtained from these preclinical studies can potentially guide future investigation of inebilizumab in patients.</description><identifier>ISSN: 2077-0383</identifier><identifier>EISSN: 2077-0383</identifier><identifier>DOI: 10.3390/jcm5120107</identifier><identifier>PMID: 27886126</identifier><language>eng</language><publisher>Switzerland: MDPI</publisher><subject>Review</subject><ispartof>Journal of clinical medicine, 2016-11, Vol.5 (12), p.107</ispartof><rights>2016 by the authors; licensee MDPI, Basel, Switzerland. 2016</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c514t-3e0eacc6e30defddee630b813ec10066c47d90c9eb5be257f5797b148288f3003</citedby><cites>FETCH-LOGICAL-c514t-3e0eacc6e30defddee630b813ec10066c47d90c9eb5be257f5797b148288f3003</cites><orcidid>0000-0003-0802-1140</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5184780/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5184780/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,37013,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27886126$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chen, Ding</creatorcontrib><creatorcontrib>Gallagher, Sandra</creatorcontrib><creatorcontrib>Monson, Nancy L</creatorcontrib><creatorcontrib>Herbst, Ronald</creatorcontrib><creatorcontrib>Wang, Yue</creatorcontrib><title>Inebilizumab, a B Cell-Depleting Anti-CD19 Antibody for the Treatment of Autoimmune Neurological Diseases: Insights from Preclinical Studies</title><title>Journal of clinical medicine</title><addtitle>J Clin Med</addtitle><description>Exaggerated or inappropriate responses by B cells are an important feature in many types of autoimmune neurological diseases. The recent success of B-cell depletion in the treatment of multiple sclerosis (MS) has stimulated the development of novel B-cell-targeting therapies with the potential for improved efficacy. CD19 has emerged as a promising target for the depletion of B cells as well as CD19-positive plasmablasts and plasma cells. Inebilizumab (MEDI-551), an anti-CD19 antibody with enhanced antibody-dependent cell-mediated cytotoxicity against B cells, is currently being evaluated in MS and neuromyelitis optica. This review discusses the role of B cells in autoimmune neurological disorders, summarizes the development of inebilizumab, and analyzes the recent results for inebilizumab treatment in an autoimmune encephalitis mouse model. The novel insights obtained from these preclinical studies can potentially guide future investigation of inebilizumab in patients.</description><subject>Review</subject><issn>2077-0383</issn><issn>2077-0383</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><recordid>eNpVkdtu1DAQhi0EolXpDQ-AfIkQgXGcxA4XSMsuh5UqQKJcW44z2XXlw2I7SOUZeGjSA6XMzYw0n_45_IQ8ZfCK8x5eXxjfshoYiAfkuAYhKuCSP7xXH5HTnC9gCSmbmonH5KgWUnas7o7J723AwTr7a_Z6eEk1fUfX6Fy1wYPDYsOOrkKx1XrD-utqiOMlnWKiZY_0PKEuHkOhcaKruUTr_RyQfsY5RRd31mhHNzajzpjf0G3IdrcvmU4pevo1oXE2XDPfyjxazE_Io0m7jKe3-YR8__D-fP2pOvvycbtenVWmZU2pOAJqYzrkMOI0jogdh0EyjoYBdJ1pxNiD6XFoB6xbMbWiFwNrZC3lxAH4CXl7o3uYB4-jWS5I2qlDsl6nSxW1Vf93gt2rXfypWiYbIa8Ent8KpPhjxlyUt9ksf9MB45zVgjVQtx3IBX1xg5oUc0443Y1hoK4cVP8cXOBn9xe7Q__6xf8A-8CY1g</recordid><startdate>20161124</startdate><enddate>20161124</enddate><creator>Chen, Ding</creator><creator>Gallagher, Sandra</creator><creator>Monson, Nancy L</creator><creator>Herbst, Ronald</creator><creator>Wang, Yue</creator><general>MDPI</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-0802-1140</orcidid></search><sort><creationdate>20161124</creationdate><title>Inebilizumab, a B Cell-Depleting Anti-CD19 Antibody for the Treatment of Autoimmune Neurological Diseases: Insights from Preclinical Studies</title><author>Chen, Ding ; Gallagher, Sandra ; Monson, Nancy L ; Herbst, Ronald ; Wang, Yue</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c514t-3e0eacc6e30defddee630b813ec10066c47d90c9eb5be257f5797b148288f3003</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Review</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chen, Ding</creatorcontrib><creatorcontrib>Gallagher, Sandra</creatorcontrib><creatorcontrib>Monson, Nancy L</creatorcontrib><creatorcontrib>Herbst, Ronald</creatorcontrib><creatorcontrib>Wang, Yue</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of clinical medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chen, Ding</au><au>Gallagher, Sandra</au><au>Monson, Nancy L</au><au>Herbst, Ronald</au><au>Wang, Yue</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Inebilizumab, a B Cell-Depleting Anti-CD19 Antibody for the Treatment of Autoimmune Neurological Diseases: Insights from Preclinical Studies</atitle><jtitle>Journal of clinical medicine</jtitle><addtitle>J Clin Med</addtitle><date>2016-11-24</date><risdate>2016</risdate><volume>5</volume><issue>12</issue><spage>107</spage><pages>107-</pages><issn>2077-0383</issn><eissn>2077-0383</eissn><abstract>Exaggerated or inappropriate responses by B cells are an important feature in many types of autoimmune neurological diseases. The recent success of B-cell depletion in the treatment of multiple sclerosis (MS) has stimulated the development of novel B-cell-targeting therapies with the potential for improved efficacy. CD19 has emerged as a promising target for the depletion of B cells as well as CD19-positive plasmablasts and plasma cells. Inebilizumab (MEDI-551), an anti-CD19 antibody with enhanced antibody-dependent cell-mediated cytotoxicity against B cells, is currently being evaluated in MS and neuromyelitis optica. This review discusses the role of B cells in autoimmune neurological disorders, summarizes the development of inebilizumab, and analyzes the recent results for inebilizumab treatment in an autoimmune encephalitis mouse model. The novel insights obtained from these preclinical studies can potentially guide future investigation of inebilizumab in patients.</abstract><cop>Switzerland</cop><pub>MDPI</pub><pmid>27886126</pmid><doi>10.3390/jcm5120107</doi><orcidid>https://orcid.org/0000-0003-0802-1140</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2077-0383
ispartof Journal of clinical medicine, 2016-11, Vol.5 (12), p.107
issn 2077-0383
2077-0383
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5184780
source Publicly Available Content Database; IngentaConnect Journals; PubMed Central
subjects Review
title Inebilizumab, a B Cell-Depleting Anti-CD19 Antibody for the Treatment of Autoimmune Neurological Diseases: Insights from Preclinical Studies
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T15%3A54%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Inebilizumab,%20a%20B%20Cell-Depleting%20Anti-CD19%20Antibody%20for%20the%20Treatment%20of%20Autoimmune%20Neurological%20Diseases:%20Insights%20from%20Preclinical%20Studies&rft.jtitle=Journal%20of%20clinical%20medicine&rft.au=Chen,%20Ding&rft.date=2016-11-24&rft.volume=5&rft.issue=12&rft.spage=107&rft.pages=107-&rft.issn=2077-0383&rft.eissn=2077-0383&rft_id=info:doi/10.3390/jcm5120107&rft_dat=%3Cproquest_pubme%3E1844025608%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c514t-3e0eacc6e30defddee630b813ec10066c47d90c9eb5be257f5797b148288f3003%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1844025608&rft_id=info:pmid/27886126&rfr_iscdi=true